Table 1. Patient characteristics.
Malignant (n = 9) | ||||||
No. | Diagnosis | Pathology | Sex | Age | CEA(ng/ml) | CA19-9(U/ml) |
M1 | Cholangiocarcinoma | Adenocarcinoma | M | 49 | 1.5 | 70.8 |
M2 | Cholangiocarcinoma | Adenocarcinoma | F | 78 | 1.6 | 35.8 |
M3 | Cholangiocarcinoma | Adenocarcinoma | M | 68 | 2.9 | 485.5 |
M4 | Cholangiocarcinoma | Adenocarcinoma | F | 74 | 1.4 | 33.1 |
M5 | Gallbladder cancer | Adenocarcinoma | F | 82 | 7.5 | 105.7 |
M6 | Gallbladder cancer | Adenocarcinoma | F | 55 | 0.5 | 6.1 |
M7 | Cholangiocarcinoma | Adenocarcinoma | F | 71 | 0.8 | 51.2 |
M8 | Cholangiocarcinoma | Adenocarcinoma | F | 78 | 1.5 | 0.8 |
M9 | Cholangiocarcinoma | Adenocarcinoma | M | 59 | 2.3 | 65 |
CEA, carcinoembryonic antigen (normal range <2.5 ng/ml); CA 19-9, carbohydrate 19-9 (normal range <37 U/ml); N.A., not applicable; W.N.L., within normal limits.